Brain, other central nervous system, and eye cancer

The Surveillance, Epidemiology, and End Results (SEER) Program provides population-based data for the descriptive epidemiology of cancer incidence and survival rates by age, sex, race, and time period according to site and various histologic categories.

Relative frequencies, incidence rates, median age at diagnosis, and 5-year relative survival rates were analyzed by histologic type for microscopically confirmed primary malignant tumors of the brain, central nervous system (CNS) (except lymphomas), and eye, as well as olfactory neuroblastomas.

Age-specific incidence rates for astrocytoma and glioblastoma, along with those for malignant meningioma, rose with increasing age up to 70-74 years, whereas rates for ependymoma and medulloblastoma (but not oligodendroglioma) showed a peak at age 0-4 years. Age-adjusted incidence rates for astrocytomas and glioblastomas were lower for blacks compared with whites, but there was little difference for rare types of brain/CNS cancers. Age-adjusted incidence rates increased slightly from 1973-1977 to 1983-1987 for astrocytoma, with little change for other histologic types. For cases diagnosed in 1983-1987, 5-year relative survival rates varied by histologic type and were low for astrocytoma, not otherwise specified (32%), and especially low for glioblastoma (4%); there was no evidence for improvement in survival rates for these two types from 1973-1977 to 1983-1987. Age-specific rates for eye melanoma rose with increasing age (especially for males), and age-adjusted rates were higher for whites than for blacks and declined from 1973-1977 to 1983-1987 in whites. Among cases diagnosed in 1983-1987, 5-year relative survival rates were high for melanoma of the eye (79%) and retinoblastoma (96%); only for retinoblastoma was there evidence of improvement in survival rates between 1973-1977 and 1983-1987.

The SEER data are useful in examining the descriptive epidemiologic features, including time trends in incidence and survival rates, for primary cancers of the brain, CNS and eye. The lack of improvement in the low survival rates for some of these cancers emphasizes the remaining therapeutic challenges.